Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.4 INR -1.54% Market Closed
Market Cap: 484.9m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Transgene Biotek Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transgene Biotek Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Transgene Biotek Ltd
BSE:526139
Other Current Assets
â‚ą10.6m
CAGR 3-Years
21%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Other Current Assets
â‚ą123.5m
CAGR 3-Years
-2%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Other Current Assets
â‚ą186.6m
CAGR 3-Years
177%
CAGR 5-Years
47%
CAGR 10-Years
48%
Hester Biosciences Ltd
NSE:HESTERBIO
Other Current Assets
â‚ą197.9m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Other Current Assets
â‚ą3B
CAGR 3-Years
-14%
CAGR 5-Years
4%
CAGR 10-Years
12%
Panacea Biotec Ltd
NSE:PANACEABIO
Other Current Assets
â‚ą616.2m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
484.9m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.28 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Transgene Biotek Ltd's Other Current Assets?
Other Current Assets
10.6m INR

Based on the financial report for Jun 30, 2024, Transgene Biotek Ltd's Other Current Assets amounts to 10.6m INR.

What is Transgene Biotek Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
43%

Over the last year, the Other Current Assets growth was 25%. The average annual Other Current Assets growth rates for Transgene Biotek Ltd have been 21% over the past three years , 43% over the past five years .

Back to Top